A Phase 2 interventional study of MET097 and Placebo in Obesity and Overweight or Obesity, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing berobenatide in Obesity — 11 open to participants now, 15 under way, 12 of them phase 3. berobenatide · Obesity.
Among the 21 studies testing berobenatide in Obesity, this one is the 12th largest by enrollment, is one of 2 that started in 2024, is one of 3 in phase 2, and was the 1st registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →11 of the 21 studies testing berobenatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 18+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Pfizer · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in Japan
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 12
First in 2024; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 239 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 258 across the 21 interventional studies. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 21 have an industry lead sponsor. The 2 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
64 studies in Obesity by Pfizer: 13 open now, 19 under way, 12 of them phase 3. Of 43 finished, 11 (26%) have results posted.
Among the 64 studies in Obesity by Pfizer, this one is the 23rd largest by enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2024, is one of 11 in phase 2, and was the 37th registered.
Pfizer’s Obesity studies by the year they started, since 2004.
5 of the studies testing berobenatide in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311850Phase 3PfizerEfficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity | 2027-09-21 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT07508241PfizerA Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity | 2027-01-27 |
| NCT07845513PfizerA Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity | 2027-02-21 |
| NCT07876531PfizerA Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity | 2027-04-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 21 studies testing berobenatide in Obesity, from their registry updates:
Among Pfizer’s 64 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks. If an individual is assigned to MET097 they will receive one of four different dose levels. Participants who have completed the first 28 weeks may participate in an exploratory extension study.
This is a multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of four different dose levels of MET097 vs. placebo for body weight loss in adult participants with obesity or overweight (body mass index [BMI] 27 to 50 kg/m2, aged 18 to 70), after 28 weeks with once weekly dosing. Participants who have completed the first 28 weeks may participate in an exploratory extension study that includes less frequent dosing regimens. After the dosing period, there is an additional post-treatment follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(BMI) at Screening of:
BMI ≥27.0 kg/m2 to \<30.0 kg/m2 with at least one of the following weight-related co-morbidities:
Stable body weight (increase or decrease ≤5 kg) within 3 months prior to Screening
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MET097 will be administered at four different dose levels subcutaneously once-weekly without titration. The extension phase includes dosing regimens that are less frequent than weekly.
Drug: MET097
Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.
Drug: Placebo
MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.
Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.
Percent Change From Baseline in Body Weight at Week 28: Part A
Analysis was performed using mixed model for repeated measures (MMRM) with treatment group, visit, and treatment by visit interaction, sex, and baseline body weight as fixed effects using unstructured covariance. The analysis excluded weight measurements after protocol specified intercurrent events (ICEs) including permanent treatment discontinuation, non-compliance to treatment and lifestyle change.
Time frame: Baseline (last non-missing measurement prior to the first dose), Week 28
Percent Change From Baseline in Body Weight at Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141 and 169: Part A
Analysis was performed using MMRM with treatment group, visit, and treatment by visit interaction, sex, and baseline body weight as fixed effects using unstructured covariance excluding weight measurements after protocol specified intercurrent ICEs.
Time frame: Baseline, Day 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141 and 169
Number of Participants With Reduction in Body Weight Greater Than or Equal to (>=) 5 Percent (%) From Baseline at Week 28: Part A
Time frame: Baseline, Week 28
Number of Participants With Reduction in Body Weight >= 10 % From Baseline at Week 28: Part A
Time frame: Baseline, Week 28
Number of Participants With Reduction in Body Weight >= 15 % From Baseline at Week 28: Part A
Time frame: Baseline, Week 28
Change From Baseline in Body Weight at Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197: Part A
Time frame: Baseline, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197
Change From Baseline in Body Mass Index (BMI) at Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197: Part A
BMI was derived from body weight in kilograms (kg) and height in meters (m), and it was calculated as weight divided by height\^2.
Time frame: Baseline, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197
Change From Baseline in Waist Circumference at Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197: Part A
Time frame: Baseline, Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, 106, 113, 141, 169 and 197
Number of Participants With Gastrointestinal (GI) Adverse Event of Clinical Interest (AECI): Part A
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered an investigational product and which did not necessarily have a causal relationship with the treatment. Gastrointestinal AECIs included nausea, vomiting and diarrhea.
Time frame: From Day 1 of dosing up to 28 days after last dose for Part A
Number of Participants With Treatment Related Gastrointestinal AECIs: Part A
An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which did not necessarily have a causal relationship with the treatment. Gastrointestinal AECIs included nausea, vomiting and diarrhea. Treatment related gastrointestinal AECIs were GI AECIs that were related to study drug and relatedness was judged by investigator.
Time frame: From Day 1 of dosing up to 28 days after last dose for Part A
Number of Participants With Gastrointestinal AECI and Treatment Related AECIs by Severity: Part A
An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which did not necessarily have a causal relationship with the treatment. Gastrointestinal AECIs included nausea, vomiting and diarrhea. Treatment related GI AECIs were GI AECIs that were related to study drug and relatedness was judged by investigator. Severity was assessed as mild: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; moderate: minimal, local or non-invasive intervention indicated, limiting age-appropriate instrumental activities of daily living and severe: medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care activities of daily living or life-threatening consequences, urgent intervention indicated or death related to an AE.
Time frame: From Day 1 of dosing up to 28 days after last dose for Part A
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs: Part A
An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which does not necessarily have a causal relationship with the treatment. A TEAE was defined as any AE which on or after exposure to study treatment. Treatment related TEAEs were TEAEs that were related to study drug and relatedness was judged by investigator.
Time frame: Up to Week 37
Number of Participants With TEAEs and Treatment-Related TEAEs by Severity: Part A
An AE was defined as any untoward medical occurrence in participant administered an investigational product and which does not necessarily have causal relationship with treatment. A TEAE was defined as any AE which on or after exposure to study treatment up to 28 days following the last dose. Treatment related TEAEs were TEAEs that were related to study drug and relatedness was judged by investigator. Severity: mild: asymptomatic/ mild symptoms, clinical/ diagnostic observations only, intervention not indicated; moderate: minimal, local/ non-invasive intervention indicated, limiting age-appropriate instrumental activities of daily living and severe: medically significant but not immediately life-threatening, hospitalization/ prolongation of hospitalization indicated, disabling, limiting self-care activities of daily living/ life-threatening consequences, urgent intervention indicated/ death related to an AE.
Time frame: Up to Week 37
Number of Participants With Abnormal Clinically Significant Physical Examination: Part A
The physical examination included examination of the following body systems (at minimum): head and neck (including complete thyroid exam), cardiovascular, respiratory, gastrointestinal, brief neurological, and general appearance. Clinical significance will be judged by investigator.
Time frame: From Day 1 of dosing up to post treatment follow up for Part A
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities: Part A
Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes. Clinical significance will be judged by investigator.
Time frame: From Day 1 of dosing up to post treatment follow up for Part A
Number of Participants With Potential Clinically Significant Laboratory Values: Part A
Laboratory parameters assessed included alanine aminotransferase (ALT) (units per liter \[U/L\]): greater than (\>) 1\*upper limit of normal (ULN), \>3\*ULN and \>5\*ULN; alkaline phosphatase (ALP) (U/L): \>2\*ULN; amylase (U/L): \>1\*ULN and \>3\*ULN; aspartate aminotransferase (AST): \>1\*ULN, \>3\*ULN and \>5\*ULN; estimated glomerular filtration rate (eGFR) (Ckd-Epi \[chronic kidney disease epidemiology collaboration\]) (milliliter per minute per 1.73m\^2): less than (\<) 60 mL/min/1.73m\^2, 60-90 mL/min/1.73m\^2 and \>90 mL/min/1.73m\^2; Lipase: \>1\*ULN and \>3\*ULN; neutrophils: \<1.5, \<0.5, 0.5 to \<1, 1 to \<1.5 and total bilirubin (milligrams per deciliter): \>2\* upper limit of normal (ULN). Potential clinical significance was judged by investigator.
Time frame: From Day 1 of dosing up to post treatment follow up for Part A
Number of Participants According to Columbia-Suicide Severity Rating Scale (C-SSRS) Categories: Part A
The C-SSRS is a questionnaire designed for the assessment of suicidal ideation and behavior in adolescents and adults. C-SSRS were evaluated through category 1 to 10. Suicidal ideation score was defined as the maximum suicidal ideation category (i.e., category 1-5), with 0 assigned if no ideation was present. Suicidal ideation, defined as 'Yes' if 'Yes' was present in any of category 1-5 and suicidal behavior, defined as 'Yes' if 'Yes' was present in any of category 6-10 and suicidal ideation or behavior, defined as 'Yes' if 'Yes' was present in any of Category 1-10.
Time frame: From Day 1 of dosing up to post treatment follow up for Part A
Patient Health Questionnaire-9 (PHQ-9) Total Score: Part A
The PHQ-9 is a questionnaire designed to monitor and measure the severity of depression in participants. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "0=not at all", "several days", "more than half the days" to "nearly every day". The total score ranges from 0 to 27 by adding score for each question (total points) where: Score 1-4: minimal depression; Score 5-9: Mild depression; Score 10-14: moderate depression; Score 15-19 moderately severe depression; Score 20-27: Severe depression. Higher score indicates greater severity of depression.
Time frame: From Day 1 of dosing up to post treatment follow up for Part A
Number of Participants With Anti Drug Antibodies (ADAs): Part A
Number of participants with baseline, positive and negative ADAs are reported in this outcome measure.
Time frame: From Day 1 of dosing up to post treatment follow up for Part A
Minimum Observed Concentration (Cmin) of Berobenatide: Part A
Time frame: From pre-dose on Day 1 up to 168 hours post-dose
Area Under the Concentration Versus Time Curve During the Dosing Interval (AUC[0-tau]) of Berobenatide: Part A
AUCtau was area under the concentration versus time curve during the dosing interval (tau), where, tau=168 hours.
Time frame: From pre-dose on Day 1 up to 168 hours post-dose
Maximum Observed Concentration (Cmax) of Berobenatide: Part A
Cmax was observed directly from data.
Time frame: From pre-dose on Day 1 up to 168 hours post-dose
Time to Maximum Concentration (Tmax) of Berobenatide: Part A
Time frame: From pre-dose on Day 1 up to 168 hours post-dose
Plasma Concentration of Berobenatide: Part A
Time frame: From pre-dose on Day 1 up to 168 hours post-dose
Percent Change From Baseline in Body Weight: Part B
Time frame: Baseline (last available measurement prior to first dose received in Part A), End of study
Number of Participants With TEAEs: Part B
An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which does not necessarily have a causal relationship with the treatment. A TEAE was defined as any AE which on or after exposure to study treatment up to 28 days following the last dose.
Time frame: From Day 1 of dosing in Part B up to 28 days after last dose for Part B
The study consisted of 2 parts: Part A and optional Part B. Eligible participants who completed Week 28 (Day 197) assessments of Part A could enter Part B. The analysis for primary outcome measures are completed and results are reported based on primary analysis when all participants completed their Week 28 visit of Part A. Analysis for secondary outcome measures are still ongoing therefore, results for all secondary outcome measures and Part B of study will be reported upon study completion.
| Milestone | Part A: Placebo QW | Part A: Berobenatide 0.4 mg QW | Part A: Berobenatide 0.6 mg QW | Part A: Berobenatide 0.9 mg QW | Part A: Berobenatide 1.2 mg QW |
|---|---|---|---|---|---|
| Started | 48 | 48 | 48 | 47 | 48 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 48 | 48 | 48 | 47 | 48 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Participant unable or unwilling to comply with study visit schedule | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Ongoing | 46 | 47 | 48 | 46 | 45 |
Analysis was performed using mixed model for repeated measures (MMRM) with treatment group, visit, and treatment by visit interaction, sex, and baseline body weight as fixed effects using unstructured covariance. The analysis excluded weight measurements after protocol specified intercurrent events (ICEs) including permanent treatment discontinuation, non-compliance to treatment and lifestyle change.
| Percent Change | Part A: Placebo QW | Part A: Berobenatide 0.4 mg QW | Part A: Berobenatide 0.6 mg QW | Part A: Berobenatide 0.9 mg QW | Part A: Berobenatide 1.2 mg QW |
|---|---|---|---|---|---|
| Percent Change From Baseline in Body Weight at Week 28: Part A | 1.67 ± 0.90 | -6.41 ± 0.89 | -8.36 ± 0.89 | -11.29 ± 0.90 | -12.45 ± 0.93 |
Analysis was performed using MMRM with treatment group, visit, and treatment by visit interaction, sex, and baseline body weight as fixed effects using unstructured covariance excluding weight measurements after protocol specified intercurrent ICEs.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
BMI was derived from body weight in kilograms (kg) and height in meters (m), and it was calculated as weight divided by height\^2.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered an investigational product and which did not necessarily have a causal relationship with the treatment. Gastrointestinal AECIs included nausea, vomiting and diarrhea.
Results for this outcome have not been posted.
An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which did not necessarily have a causal relationship with the treatment. Gastrointestinal AECIs included nausea, vomiting and diarrhea. Treatment related gastrointestinal AECIs were GI AECIs that were related to study drug and relatedness was judged by investigator.
Results for this outcome have not been posted.
An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which did not necessarily have a causal relationship with the treatment. Gastrointestinal AECIs included nausea, vomiting and diarrhea. Treatment related GI AECIs were GI AECIs that were related to study drug and relatedness was judged by investigator. Severity was assessed as mild: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; moderate: minimal, local or non-invasive intervention indicated, limiting age-appropriate instrumental activities of daily living and severe: medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care activities of daily living or life-threatening consequences, urgent intervention indicated or death related to an AE.
Results for this outcome have not been posted.
An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which does not necessarily have a causal relationship with the treatment. A TEAE was defined as any AE which on or after exposure to study treatment. Treatment related TEAEs were TEAEs that were related to study drug and relatedness was judged by investigator.
Results for this outcome have not been posted.
An AE was defined as any untoward medical occurrence in participant administered an investigational product and which does not necessarily have causal relationship with treatment. A TEAE was defined as any AE which on or after exposure to study treatment up to 28 days following the last dose. Treatment related TEAEs were TEAEs that were related to study drug and relatedness was judged by investigator. Severity: mild: asymptomatic/ mild symptoms, clinical/ diagnostic observations only, intervention not indicated; moderate: minimal, local/ non-invasive intervention indicated, limiting age-appropriate instrumental activities of daily living and severe: medically significant but not immediately life-threatening, hospitalization/ prolongation of hospitalization indicated, disabling, limiting self-care activities of daily living/ life-threatening consequences, urgent intervention indicated/ death related to an AE.
Results for this outcome have not been posted.
The physical examination included examination of the following body systems (at minimum): head and neck (including complete thyroid exam), cardiovascular, respiratory, gastrointestinal, brief neurological, and general appearance. Clinical significance will be judged by investigator.
Results for this outcome have not been posted.
Twelve lead ECGs were measured with the participant in a supine position after at least 5 minutes. Clinical significance will be judged by investigator.
Results for this outcome have not been posted.
Laboratory parameters assessed included alanine aminotransferase (ALT) (units per liter \[U/L\]): greater than (\>) 1\*upper limit of normal (ULN), \>3\*ULN and \>5\*ULN; alkaline phosphatase (ALP) (U/L): \>2\*ULN; amylase (U/L): \>1\*ULN and \>3\*ULN; aspartate aminotransferase (AST): \>1\*ULN, \>3\*ULN and \>5\*ULN; estimated glomerular filtration rate (eGFR) (Ckd-Epi \[chronic kidney disease epidemiology collaboration\]) (milliliter per minute per 1.73m\^2): less than (\<) 60 mL/min/1.73m\^2, 60-90 mL/min/1.73m\^2 and \>90 mL/min/1.73m\^2; Lipase: \>1\*ULN and \>3\*ULN; neutrophils: \<1.5, \<0.5, 0.5 to \<1, 1 to \<1.5 and total bilirubin (milligrams per deciliter): \>2\* upper limit of normal (ULN). Potential clinical significance was judged by investigator.
Results for this outcome have not been posted.
The C-SSRS is a questionnaire designed for the assessment of suicidal ideation and behavior in adolescents and adults. C-SSRS were evaluated through category 1 to 10. Suicidal ideation score was defined as the maximum suicidal ideation category (i.e., category 1-5), with 0 assigned if no ideation was present. Suicidal ideation, defined as 'Yes' if 'Yes' was present in any of category 1-5 and suicidal behavior, defined as 'Yes' if 'Yes' was present in any of category 6-10 and suicidal ideation or behavior, defined as 'Yes' if 'Yes' was present in any of Category 1-10.
Results for this outcome have not been posted.
The PHQ-9 is a questionnaire designed to monitor and measure the severity of depression in participants. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "0=not at all", "several days", "more than half the days" to "nearly every day". The total score ranges from 0 to 27 by adding score for each question (total points) where: Score 1-4: minimal depression; Score 5-9: Mild depression; Score 10-14: moderate depression; Score 15-19 moderately severe depression; Score 20-27: Severe depression. Higher score indicates greater severity of depression.
Results for this outcome have not been posted.
Number of participants with baseline, positive and negative ADAs are reported in this outcome measure.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
AUCtau was area under the concentration versus time curve during the dosing interval (tau), where, tau=168 hours.
Results for this outcome have not been posted.
Cmax was observed directly from data.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
An AE was defined as any untoward medical occurrence in a participant administered an investigational product and which does not necessarily have a causal relationship with the treatment. A TEAE was defined as any AE which on or after exposure to study treatment up to 28 days following the last dose.
Results for this outcome have not been posted.
Collected over From Day 1 of dosing up to 28 days after last dose of study treatment (Week 32) for Part A. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Placebo QW | 0/48 (0%) | 0/48 (0%) | 30/48 (62.5%) |
| Part A: Berobenatide 0.4 mg QW | 0/48 (0%) | 2/48 (4.2%) | 33/48 (68.8%) |
| Part A: Berobenatide 0.6 mg QW | 0/48 (0%) | 1/48 (2.1%) | 34/48 (70.8%) |
| Part A: Berobenatide 0.9 mg QW | 0/47 (0%) | 0/47 (0%) | 30/47 (63.8%) |
| Part A: Berobenatide 1.2 mg QW | 0/48 (0%) | 0/48 (0%) | 35/48 (72.9%) |
| Event | Part A: Placebo QW | Part A: Berobenatide 0.4 mg QW | Part A: Berobenatide 0.6 mg QW | Part A: Berobenatide 0.9 mg QW | Part A: Berobenatide 1.2 mg QW |
|---|---|---|---|---|---|
| Obstructive pancreatitisGastrointestinal disorders | 0/48 | 1/48 | 0/48 | 0/47 | 0/48 |
| Appendicitis perforatedInfections and infestations | 0/48 | 1/48 | 0/48 | 0/47 | 0/48 |
| Alcohol poisoningInjury, poisoning and procedural complications | 0/48 | 0/48 | 1/48 | 0/47 | 0/48 |
| Event | Part A: Placebo QW | Part A: Berobenatide 0.4 mg QW | Part A: Berobenatide 0.6 mg QW | Part A: Berobenatide 0.9 mg QW | Part A: Berobenatide 1.2 mg QW |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 13/48 | 15/48 | 17/48 | 16/47 | 24/48 |
| VomitingGastrointestinal disorders | 6/48 | 11/48 | 8/48 | 13/47 | 12/48 |
| Upper respiratory tract infectionInfections and infestations | 9/48 | 12/48 | 10/48 | 4/47 | 12/48 |
| Decreased appetiteMetabolism and nutrition disorders | 7/48 | 10/48 | 12/48 | 10/47 | 8/48 |
| ConstipationGastrointestinal disorders | 8/48 | 10/48 | 11/48 | 11/47 | 4/48 |
| DiarrhoeaGastrointestinal disorders | 5/48 | 8/48 | 5/48 | 6/47 | 11/48 |
| HeadacheNervous system disorders | 7/48 | 11/48 | 8/48 | 7/47 | 10/48 |
| DyspepsiaGastrointestinal disorders | 1/48 | 7/48 | 5/48 | 7/47 | 7/48 |
| Abdominal distensionGastrointestinal disorders | 2/48 | 2/48 | 0/48 | 1/47 | 7/48 |
| FatigueGeneral disorders | 3/48 | 7/48 | 2/48 | 6/47 | 6/48 |
The full analysis set (FAS) included all randomized participants.
| Age, Continuous(Years) | Part A: Placebo QW | Part A: Berobenatide 0.4 mg QW | Part A: Berobenatide 0.6 mg QW | Part A: Berobenatide 0.9 mg QW | Part A: Berobenatide 1.2 mg QW | Total |
|---|---|---|---|---|---|---|
| Mean | 40.0 ± 11.45 | 38.8 ± 11.31 | 41.1 ± 12.45 | 39.9 ± 12.65 | 41.5 ± 10.77 | 40.3 ± 11.69 |
| Sex: Female, Male(Participants) | Part A: Placebo QW | Part A: Berobenatide 0.4 mg QW | Part A: Berobenatide 0.6 mg QW | Part A: Berobenatide 0.9 mg QW | Part A: Berobenatide 1.2 mg QW | Total |
|---|---|---|---|---|---|---|
| Female | 33 | 32 | 28 | 27 | 31 | 151 |
| Male | 15 | 16 | 20 | 20 | 17 | 88 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Placebo QW | Part A: Berobenatide 0.4 mg QW | Part A: Berobenatide 0.6 mg QW | Part A: Berobenatide 0.9 mg QW | Part A: Berobenatide 1.2 mg QW | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 31 | 38 | 32 | 33 | 42 | 176 |
| Not Hispanic or Latino | 16 | 9 | 16 | 13 | 6 | 60 |
| Unknown or Not Reported | 1 | 1 | 0 | 1 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Part A: Placebo QW | Part A: Berobenatide 0.4 mg QW | Part A: Berobenatide 0.6 mg QW | Part A: Berobenatide 0.9 mg QW | Part A: Berobenatide 1.2 mg QW | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 1 | 2 | 3 | 3 | 1 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 13 | 2 | 13 | 6 | 4 | 38 |
| White | 32 | 40 | 29 | 35 | 41 | 177 |
| More than one race | 1 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 1 | 4 | 2 | 3 | 2 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Oct 2024 to primary completion in Jul 2025, 8 months.
Results were first posted in Aug 2026, 1 year 1 month after primary completion.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 8 months is below that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Berobenatide